Two-staged exchange arthroplasty with an antibiotic-impregnated PMMA cement spacer in-between two stages has a success rate of 85% to 95% in eradication of infection. Use of vancomycine in high doses has a high potential for complications due to nephrotoxicity.

The aim of this study was to evaluate the results of two-staged exchange arthroplasty in infected hip arthroplasty using low-dose vancomycine-impregnated PMMA cement as an interim spacer between stages.

Thirty-five (20 females, 15 males, average age: 60) patients with a confirmed infected total hip arthroplasty who were treated between 1999 and 2005 were the subjects of the study. In the first stage after removal of the prosthesis and debridement, a spacer made of 40 grams of PMMA cement impregnated with 1 gr vancomycine was placed in the infected joint space. Postoperatively, patients were treated with 6 weeks of intravenous antibiotics in consultation with an infectious disease consultant. When CRP and ESR returned to normal levels, revision surgery with cementless components was performed.

The average follow-up after the second stage was 4 years. The ESR and CRP decreased significantly before the second stage with this treatment protocol (from 81.28 to 17.54 mm/h p< 0.001 and 10.05 to 0.64 mg/dl respectively, p< 0.001). The mean interval between the two stages was 193.3 days. A second debridement was needed in 4 patients (10.8 %) because they did not respond to treatment. Two patients (5.4 %) had recurrent infections after reimplantation and underwent a resection arthroplasty. None of the patients suffered from antibiotic toxicity.

Two-stage exchange arthroplasty using a low dose vancomycine-impregnated cement spacer was an effective method in treating infected hip replacements. With using a lower dose than previously reported, we were able to avoid antibiotic toxicity while effectively treating our patients with the same success rate.

Two-stage exchange revision is the gold standard in treating an infected total hip arthroplasty. The new emerging gold standard appears to be using an antibiotic impregnated spacer made from polymethylmeta-crylate (PMMA) bone cement between two stages. However, a consensus has not been reached on the antibiotic to use in the cement and its dose. Vancomycin an aminoglycoside is widely used for this purpose in the PMMA cement in doses such as 3 to 9 gr per 40 gr polymer powder. The purpose of this study was to see if Vancomycin is as effective in safer low doses of 1 gr per 40 gr polymer powder.Between 1997 and 2002, twenty-six patients were treated for an infected hip arthroplasty with a two-stage exchange arthroplasty using a Vancomycin impregnated polymethylmetacrylate (PMMA) bone cement spacer. During the first stage all prosthetic material was removed and after debridement, irrigation an articulating spacer was made from PMMA cement (Surgical Simplex, Howmedica, Rutherford, NJ, USA). One gram of Vancomycin HCl (Vancomycin, Eli Lilly, USA) powder was added to each 40 gr polymer powder prior to curing the cement. After the first stage parenteral antibiotics were administered for six weeks. When erythrocyte sedimentation rate and the CRP returned to a normal level, the patient underwent the second stage were a cementless prosthesis was inserted. Intra-operative cultures and frozen sections obtained during the second stage were negative in all patients indicating successful treatment of the infection. Mean follow up after the second stage was 36 (range 24 to 74) months. Two patients had a reinfection after four months. These two patients were infected with gram-negative micro-organisms. This gave us a 92 percent infection eradication rate at 3 years. None of the patients suffered from Vancomycin related side effects.In this study we used a lower dose (1 gr per 40 gr polymer powder) of Vancomycin in the PMMA spacer instead of the commonly used 3 to 9 gr per 40 gr polymer powder. The reason for this was our concerns for nephrotoxicity and allergic reactions frequently associated with use of Vancomycin. Antibiotics are used in cement spacers as a disinfecting agent and sterilizer of dead spaces. As Vancomycin is highly effective when used in PMMA due to its elution dynamics and thermostability we believed it would be effective even in low doses. In all patients the infection appeared to be cured after the first stage. This was demonstrated with negative intraoperative cultures and frozen sections. However, we had two reinfections in patients that initially were infected with gram-negative organism, which Vancomycin is not as effective. Despite this we were able to sterilize the infected hip with a low dose approach in the first stage. Vancomycin is effective in low dose when used in PMMA cement spacers for infected total hip arthroplasties. This approach will decrease potential serious side effects of Vancomycin.